NOTICE TO CONVENE THE

Annual General Meeting

2021
Notice to convene the Annual General Meeting of

Chr. Hansen Holding A/S

To the shareholders of Chr. Hansen Holding A/S

The Board of Directors has the pleasure of convening the Annual General Meeting to be held on

Wednesday November 24, 2021 at 4:00 p.m. CET

at Søhuset Konferencecenter, Venlighedsvej 10, 2970 Hørsholm, Denmark.

Agenda

1. Report on the Company’s activities
2. Approval of the 2020/21 Annual Report
3. Resolution on the appropriation of profit
4. Presentation of the Company’s 2020/21 Remuneration Report for an advisory vote
5. Resolution on remuneration of members of the Board of Directors
6. Proposals from the Board of Directors
   6a. Approval of indemnification arrangements and related amendment of the Remuneration Policy
7. Election of members to the Board of Directors
   7a. Election of a chair of the Board of Directors
   7b. Election of other members to the Board of Directors
8. Election of a company auditor
   8a. Re-election of PwC Statsautoriseret Revisionspartnerselskab
9. Authorisation of the chair of the Annual General Meeting

Full proposals for the items on the agenda:

Re item 1 on the agenda
The Board of Directors proposes that the Annual General Meeting takes note of the Board of Directors’ report on the Company’s activities in 2020/21.

Re item 2 on the agenda

Re item 3 on the agenda
The Board of Directors proposes that the Annual General Meeting approves the Board of Directors’ proposal for the appropriation of profit as stated in the Annual Report for 2020/21, including a proposal to distribute an ordinary dividend of DKK 6.54 per share of DKK 10 in connection with the Annual General Meeting, corresponding to an amount of EUR 116 million or 58% of the profit of the Chr. Hansen Group for the year.
**Re item 4 on the agenda**
The Board of Directors proposes that the Annual General Meeting approves the Company’s Remuneration Report for 2020/21.

The Remuneration Report has been prepared in accordance with applicable rules and corporate governance recommendations. The report aims to further enhance transparency in relation to remuneration paid by the Company. The report covers remuneration awarded or due in the course of the financial year 2020/21 to the Company’s Board of Directors and Executive Board. The Executive Board includes executive management members registered as such with the Danish Business Authority.


**Re item 5 on the agenda**
The base fee of the Board of Directors was most recently adjusted in 2016. Based on a review of the remuneration of the Board of Directors, including current remuneration levels of listed companies (both generally and within comparable industries), the Board of Directors proposes an adjustment of the current base fee of DKK 400,000 of plus 5% resulting in the following remuneration level for 2021/22:

<table>
<thead>
<tr>
<th>Position</th>
<th>Fee (DKK)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Members of the Board of Directors</td>
<td>420,000</td>
</tr>
<tr>
<td>Chair of the Board of Directors</td>
<td>1,260,000</td>
</tr>
<tr>
<td>Vice Chair of the Board of Directors</td>
<td>840,000</td>
</tr>
</tbody>
</table>

The Board of Directors has established an Audit Committee, a Nomination Committee, a Remuneration Committee and a Science & Innovation Committee. Based on the remuneration review conducted by the Board of Directors and in line with the practice of other C25 companies, the Board of Directors proposes to introduce fixed multipliers for committee fees based on the board base fee corresponding to the current ratio between the board base fee and committee fees. Thus, the Board of Directors proposes committee members receive the following supplementary fees for the financial year 2021/22:

<table>
<thead>
<tr>
<th>Committee</th>
<th>Fee (DKK)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair of the Audit Committee</td>
<td>315,000</td>
</tr>
<tr>
<td>Chair of the Remuneration and Science &amp; Innovation Committees</td>
<td>262,500</td>
</tr>
<tr>
<td>Chair of the Nomination Committee</td>
<td>210,000</td>
</tr>
<tr>
<td>Members of the Audit and Science &amp; Innovation Committees</td>
<td>157,500</td>
</tr>
<tr>
<td>Members of the Nomination and Remuneration Committees</td>
<td>131,250</td>
</tr>
</tbody>
</table>

In addition to the above fees, the Board of Directors proposes that board members and committee members be entitled to the following differentiated fixed travel allowances, when travelling for a Board and/or committee related meeting, dependent on the travelling distance:

<table>
<thead>
<tr>
<th>Traveling Outside Country of Residence</th>
<th>Traveling Between Continents</th>
</tr>
</thead>
<tbody>
<tr>
<td>DKK 22,500 (unchanged compared to the remuneration level for 2020/21)</td>
<td>DKK 37,500 (unchanged compared to the remuneration level for 2020/21)</td>
</tr>
</tbody>
</table>

In addition, the Company pays social security duties and similar taxes imposed by foreign authorities in relation to the board members’ fees.
Re item 6a on the agenda
Recent developments in the insurance market have affected the pricing and the terms and conditions of directors and officers insurance for listed companies. To ensure the Company’s ability to continue to attract talent and offer appropriate coverage and protection to the Board of Directors and Executive Board, it is therefore proposed that the Company – in cases where the Board of Directors considers the available insurance coverage is insufficient and/or associated with disproportionate costs – may provide indemnification arrangements to its Board of Directors and Executive Board. Any such indemnification presupposes the absence of fraud or willful misconduct.

It is further proposed that the resolution be reflected in the Company’s Remuneration Policy by including the following new Section 2.6 therein:

“2.6 Directors’ and officers’ insurance and indemnification

The Company may take out directors’ and officers’ liability insurance covering members of the Board of Directors and the Executive Board. In cases where the Board of Directors considers that the available insurance coverage is insufficient and/or associated with disproportionate costs or other adverse terms, the Company may provide indemnity arrangements for the members of the Board of Directors and/or the Executive Board in respect of claims relating to the exercise of their duties, provided in each case such claims are not caused by such member’s fraud or willful misconduct. The Company may in this respect also offer to cover reasonable costs associated with the defense against such claims.”

The revised Remuneration Policy is attached as Annex 1 to this notice.

Re item 7a on the agenda
The Board of Directors proposes re-election for a one-year term of Dominique Reiniche as Chair of the Board of Directors.

Re item 7b on the agenda
The Board of Directors proposes that the Annual General Meeting re-elect the following board members for one-year terms: Jesper Brandgaard, Luis Cantarell, Lise Kaae, Heidi Kleinbach-Sauter, Kevin Lane and Lillie Li Valeur. Board member Mark Wilson has informed the Board of Directors that he will not seek re-election at the Annual General Meeting.

If all proposed board candidates are re-elected, the Board of Directors will consist of seven shareholder-elected board members, which will bring the number of shareholder-elected members back to a normalized level.

A detailed description of the candidates’ competencies and managerial positions held in other commercial enterprises is attached as Annex 2 to this convening notice and can also be found on the Company’s website, www.chr-hansen.com.

It is noted that in June 2021, the employees of Chr. Hansen Holding A/S and Chr. Hansen A/S conducted an election of employee representatives to the Board of Directors. Charlotte Hemmingsen and Kim Ib Sørensen were re-elected, while Casper Lynghøj Giedo and Karen Lauesen were elected as new employee representatives for a period of four years and will be joining the Board of Directors immediately following the Annual General Meeting.

Re item 8a on the agenda
The Board of Directors proposes that the Company’s current auditor, PwC Statsautoriseret Revisionspartnerselskab be re-elected.

The Audit Committee has not been influenced by third parties, and the Company is not subject to any contractual obligation limiting the Annual General Meeting’s choice to certain auditors or audit firms.

Re items 9 on the agenda
The Board of Directors proposes that the Annual General Meeting authorises the chair of the Annual General Meeting (with a right of substitution) to file the resolutions passed with the Danish Business Authority and to make any such changes and additions as the Danish Business Authority may require as a condition for registering or approving the resolutions passed.
**Majority requirement**
All proposals may be adopted by a simple majority of votes. The proposal under agenda item 4 regarding the remuneration report is in accordance with the Danish Companies Act subject to an advisory vote only.

**The company’s share capital**
At the time of convening the Annual General Meeting, the Company’s share capital has a nominal value of DKK 1,318,524,960, divided into shares of DKK 10 each. Each share of DKK 10 carries one vote.

**Date of registration and shareholders’ voting rights**
The date of registration (record date) is **Wednesday November 17, 2021**.
Shareholders who hold shares in the Company on the date of registration are entitled to attend and vote at the Annual General Meeting. The shares held by each individual shareholder are calculated at the date of registration (end of day) based on the record of the shareholder’s shares in the register of shareholders as well as any notices concerning ownership received by the Company for recording in the register of shareholders. Attendance is furthermore subject to the shareholder obtaining an admission card in due time as further described below.

**Admission cards**
Shareholders who wish to attend the Annual General Meeting must request an admission card no later than **Friday November 19, 2021**.

Admission cards for the Annual General Meeting may be obtained as follows:

- Electronically through the “Shareholder Portal” under the menu “Investors” on the Company’s website, [www.chr-hansen.com](http://www.chr-hansen.com), or on the website of Computershare A/S, [www.computershare.dk](http://www.computershare.dk).

- By returning the signed and completed form to Computershare A/S either by e-mailing a scanned copy of the form to [gf@computershare.dk](mailto:gf@computershare.dk) or by sending it by ordinary mail to Computershare A/S, Lottenborgvej 26 D, 1. Sal, 2800 Kgs. Lyngby, Denmark. The form is available on the Company’s website, [www.chr-hansen.com](http://www.chr-hansen.com), through the “Shareholder Portal” under the menu “Investors”.

- By contacting Computershare A/S by phone **+45 45 46 09 97** (weekdays between 09:00 a.m. and 3:30 p.m. CET) or by e-mail to [gf@computershare.dk](mailto:gf@computershare.dk).

Duly requested admission cards will be sent electronically to the e-mail address provided by the shareholder in the Shareholder Portal and which has been registered in the register of shareholders. Accordingly, admission cards will no longer be distributed to the shareholders by ordinary mail.

Shareholders must present admission cards at the Annual General Meeting either electronically on a smartphone/tablet or in a printed version. Shareholders, who have requested admission cards without specifying an email address, are required to collect their admission card at the door upon presentation of proof of identity. Printed voting cards will be handed out at the door.
**Proxy voting**
Shareholders unable to attend the Annual General Meeting may attend by proxy. Proxies may be issued as follows:

- Electronically through the “Shareholder Portal” under the menu “Investors” on the Company’s website, [www.chr-hansen.com](http://www.chr-hansen.com)
- In writing using the proxy form available on the Company’s website, [www.chr-hansen.com](http://www.chr-hansen.com), through the “Shareholder Portal” under the menu “Investors”. The signed and completed proxy form must be returned to Computershare A/S either by e-mailing a scanned copy of the form to [gf@computershare.dk](mailto:gf@computershare.dk) or by sending it by ordinary mail to Computershare A/S, Lottborgvæj 26 D, 1. Sal, 2800 Kgs. Lyngby, Denmark

The completed proxy form must reach Computershare A/S no later than **Friday November 19, 2021**. It is possible to either issue a proxy or to vote by postal vote (see below), but not both.

Due documentation proving the right to attend and vote by proxy must be presented. Failure to present such documentation may result in the right to attend and/or vote being denied.

**Postal voting**
Shareholders unable to attend the Annual General Meeting may vote by postal vote. Postal votes may be submitted as follows:

- Electronically through the “Shareholder Portal” under the menu “Investors” on the Company’s website, [www.chr-hansen.com](http://www.chr-hansen.com)
- In writing using the form available on the Company’s website, [www.chr-hansen.com](http://www.chr-hansen.com), through the “Shareholder Portal” under the menu “Investors”. The signed and completed form must be returned to Computershare A/S either by e-mailing a scanned copy of the form to [gf@computershare.dk](mailto:gf@computershare.dk) or by sending it by ordinary mail to Computershare A/S, Lottborgvæj 26 D, 1. Sal, 2800 Kgs. Lyngby, Denmark

Postal votes must reach Computershare A/S no later than **Friday November 19, 2021**. It is possible to either vote by postal vote or to issue a proxy (see above), but not both.

**Practical information**
Distribution of dividends adopted at the Annual General Meeting will be effected by VP Securities A/S on **November 29, 2021**.

Until and including the day of the Annual General Meeting, additional information concerning the Annual General Meeting will be available on the Company’s website, [www.chr-hansen.com](http://www.chr-hansen.com), including:
• This notice to convene the Annual General Meeting, including Annex 1 and Annex 2

• Forms to be used for voting by proxy or by postal vote

• Information on the total number of shares and votes at the date of the notice to convene the Annual General Meeting

• The 2020/21 Annual Report

• The 2020/21 Remuneration Report

• Information on handling of personal information in connection with the Annual General Meeting.

The Annual General Meeting will be held in English and broadcast directly by webcast on the Company’s website, www.chr-hansen.com. Simultaneous interpretation from English to Danish will be available at the meeting.

Coffe and tea will be served after the meeting

Questions from shareholders
Shareholders are welcome to submit written questions to the Company concerning the agenda or the documents, etc. to be considered at the Annual General Meeting. Such questions should be submitted by ordinary mail to the Company’s offices at Bage Allé 10-12, 2970 Hørsholm, Denmark, on www.chr-hansen.com or by e-mail to investorrelations@chr-hansen.com, and must reach the Company at least one week prior to the date of the Annual General Meeting.

Hørsholm, October 28, 2021

Chr. Hansen Holding A/S
Board of Directors

ANNEX 1 – Revised Remuneration Policy
ANNEX 2 – Description of the candidates for the Board of Directors
**Annex 1**

Remuneration Policy for Chr. Hansen Holding A/S

1. Introduction

The Board of Directors of Chr. Hansen Holding A/S ("Chr. Hansen" or the "Company", and jointly with its subsidiaries, the "Group") has adopted this Remuneration Policy (the "Remuneration Policy") applicable to the Company’s Board of Directors and Executive Board. The Executive Board includes all the executives registered as executives with the Danish Business Authority.

The Remuneration Policy is prepared in accordance with sections 139 and 139a of the Danish Companies Act and the Recommendations on Corporate Governance issued by the Danish Committee on Corporate Governance.

This Remuneration Policy of November 24, 2021 replaces, amends and restates the Remuneration Policy for Chr. Hansen Holding A/S adopted at the Annual General Meeting held November 27, 2019 and the Overall guidelines for incentive-based remuneration for Chr. Hansen Holding A/S’ management adopted at the Annual General Meeting held November 26, 2015.

The Remuneration Policy forms the basis for the framework governing remuneration of the Company’s Board of Directors and Executive Board.

2. General principles

2.1 Overall objectives

The remuneration of Chr. Hansen’s Board of Directors and Executive Board shall contribute towards ensuring that the Company is able to attract and retain highly qualified members to its Board of Directors and Executive Board. The remuneration and its composition shall be structured so as to create a suitable alignment of the interests of management and those of the shareholders. In this context, the remuneration shall contribute towards promoting the strategy, long-term sustainability and creation of value in the Chr. Hansen Group by supporting the Group’s long-term and short-term objectives.

2.2 Incentive Pay

Incentive pay forms an integral part of remuneration to the Executive Board. The incentive-based remuneration shall be specifically designed to seek to attain a suitable alignment of the interests of the Executive Board and those of the shareholders and to ensure that Chr. Hansen is able to attract and retain highly qualified executive officers. Any decision to introduce incentive-based remuneration, including the size and the composition of the remuneration, shall be made on the basis of what the Remuneration Committee and the Board of Directors deem suitable to promote abovementioned objectives. The Executive Board’s remuneration, including the nature and level of incentive pay, is assessed on an ongoing basis in the light of the remuneration level in other Danish large-cap companies with international activities as well as European companies, which operate within similar industries as the Company.
2.3 Performance targets
Generally, incentive-based remuneration shall be subject to the achievement of certain performance targets. The Board of Directors determines the performance targets for each member of the Executive Board and in respect of each incentive program based on recommendations from Chr. Hansen’s Remuneration Committee. The performance targets shall reflect the Group’s business targets, which may be both financial or non-financial and which may relate to the entire Group, to one or more business areas/divisions, to one or more Group companies, to the performance of the individual executive officer, and/or to the occurrence of specific events. When defining the performance targets the Board of Directors shall take into account the incentive programs’ effect not only in relation to the Company’s performance, but also in relation to its long-term sustainability. In this respect, the Board of Directors shall ensure that the incentive programs do not promote unnecessary risk taking or contravene the Company’s overall CSR policies and objectives. The performance targets actually applied for each incentive program will be described in general terms in the Company’s Remuneration Report.

The level of achievement of individual performance targets and thus the size of remuneration payment to the individual Executive Board member shall in each case be determined by the Board of Directors based on recommendations from the Remuneration Committee.

2.4 Relationship to remuneration paid to employees
In preparing the Remuneration Policy and the individual executive employment contracts, the Board of Directors takes into account the pay and employment conditions of the Company’s other employees. The Board of Directors considers an appropriate balance between employee and management remuneration is achieved, considering both market practice for remuneration in comparable listed companies and considering the responsibilities and duties of the members of the Executive Board compared to other employees.

The principles for short-term incentives for key employees in the Company and for the Executive Board are aligned.

Long-term incentive programs are not generally offered to the Company’s other employees. The Board of Directors finds that the long-term incentive program outlined herein is appropriate and required in order to align the interests of those with management responsibilities with the interests of the Company and its shareholders. For the same reason, this long-term incentive program outlined herein is also extended to the Company’s broader Corporate Leadership Team (CLT).

With regard to terms of resignation, the Board of Directors considers that the comparatively longer resignation periods for the members of the Executive Board reflect market practice and are appropriate as part of the overall remuneration package to the members of the Executive Board.

2.5 Conflicts of interests
In order to avoid conflicts of interest in relation to the remuneration of the Board of Directors, the Remuneration Policy and the remuneration of the Board of Directors shall be approved by the General Meeting. In respect of the Executive Board, the remuneration shall in each case be based on the recommendations of the Remuneration Committee and shall be approved by the Board of Directors. The Company and the Remuneration Committee shall use external advisers that are not the same as those used by the Executive Board.
2.6 Directors’ and officers’ insurance and indemnification
The Company may take out directors’ and officers’ liability insurance covering members of the Board of Directors and the Executive Board. In cases where the Board of Directors considers that the available insurance coverage is insufficient and/or associated with disproportionate costs or other adverse terms, the Company may provide indemnity arrangements for the members of the Board of Directors and/or the Executive Board in respect of claims relating to the exercise of their duties, provided in each case such claims are not caused by such member’s fraud or willful misconduct. The Company may in this respect also offer to cover reasonable costs associated with the defense against such claims.

3. Principles for the Board of Directors’ remuneration
Members of the Company’s Board of Directors receive a cash fee but no incentive-based remuneration.

The remuneration is composed of a fixed annual base fee that is the same for all Board members. In addition, the Chair and the Vice Chair of the Board of Directors, and the Board members that are either chair or a member of a permanent committee, receive an annual supplementary fee.

The amount of the fixed annual base fee and supplementary fees for the current financial year must be approved by the General Meeting based on a proposal from the Board of Directors. The Board of Directors’ proposal is fixed on the basis of the Remuneration Committee’s recommendations. The Remuneration Committee’s recommendations must be based upon market practice, the scope and nature of the work and the qualifications required.

If the Board of Directors instructs a Board member to perform specific tasks on an ad hoc basis, which fall outside the scope of the Board of Directors’ ordinary duties, the Board member in question may – subject to the prior or subsequent approval of the General Meeting – receive separate supplementary remuneration in this regard.

In addition to the above fees, the Company pays social security duties and similar taxes imposed by foreign authorities in relation to the Board members’ fees. The Company reimburses Board members for relevant expenses, such as travel and accommodation, in connection with Board and committee related meetings as well as relevant education. In addition, Board members receive a fixed travel allowance in connection with travel to Board and committee related meetings outside their country of residence.

Information on remuneration paid to the Board of Directors is disclosed in the Company’s Remuneration Report.

Each Board member elected by the General Meeting must not later than 12 months after the appointment to the Board of Directors purchase shares in the Company corresponding to an amount of at least one year’s base fee. The Board member must pursuant to an internal process maintain a shareholding corresponding to at least one year’s base fee for as long as he/she is a member of the Company’s Board of Directors.

4. Principles for the Executive Board’s remuneration
4.1 Base salary, benefits, resignation and pension
Each member of the Executive Board receives an agreed base salary with addition of pension contribution subject to annual reassessment.

Executive Board members receive pension contributions equal to 20% of base salary. The pension contributions are paid to the Company’s designated third party pension providers. The third party pension contribution schemes
arranged by the Company are offered on market terms and do not involve any pension payment obligations on the part of the Group.

The Remuneration Committee makes recommendations to the Board of Directors with regard to the base salary. The Remuneration Committee’s recommendations must be based on market practice, the scope and nature of the work, the qualifications required and the performance of each individual executive officer. In addition, Chr. Hansen’s interest in attracting, motivating and retaining qualified executive officers must in general be taken into account.

Members of the Executive Board may be granted certain ordinary employment benefits, e.g. company car, insurance, newspaper, free telephone and internet access. Depending on the Executive Board members’ individual circumstances, Executive Board members may also receive relocation related benefits such as housing allowance, school tuition fee allowance and reimbursement of tax and other relocation costs. The employment benefits and any additional relocation related benefits represents only a relatively small proportion of total remuneration expenses and will typically not exceed 20% of the base salary of the individual executive.

The Board of Directors determines the specific employment terms in relation to resignation based on the Remuneration Committee’s recommendations. The ordinary notice period on the part of the Company cannot exceed 18 months. The individual executive officer may terminate his/her employment subject to at least an ordinary notice period of 12 months. The Company does not apply extended notice periods in the event of change-of-control or similar structural changes. The aggregate severance pay, including salary during notice periods (but excluding any incentive programs granted prior to termination), cannot exceed an amount corresponding to the remuneration paid for the two preceding years (also excluding any incentive remuneration granted prior to the two-year period).

4.2 Incentive-based remuneration

Members of the Executive Board may be offered incentive-based remuneration in accordance with the principles set out below.

The incentive-based remuneration for the Executive Board of Chr. Hansen may at the sole discretion of the Board of Directors comprise (i) any kind of cash bonus agreement, (ii) grant of restricted share units (“RSUs”), i.e. rights to receive shares against no or only nominal consideration, (iii) matching shares or (iv) extraordinary incentive-based remuneration as a one-off bonus (see clause 4.5).

The incentive-based remuneration may be granted on an ongoing basis (rolling grants) and, if considered relevant by the Board of Directors, on an ad hoc basis in relation to specific events.

When determining the composition of the incentive-based remuneration and the ratio between the incentive-based remuneration and the base salary, the Board of Directors must carefully consider the overall objectives of the Remuneration Policy and aim to avoid undesirable incentives for the Executive Board.

4.2.1 Short-term incentives in the form of Cash bonus and/or RSUs

Members of the Executive Board may be granted short-term incentives on an annual basis conditional upon achievement in whole or in part of certain individual performance targets related to the relevant financial year.

The performance targets will in accordance with clause 2.3 above be defined by the Board of Directors (based on recommendations from the Remuneration Committee) and shall primarily relate to and support the Company’s short-term objectives.
Short-term incentives may as further determined by the Board of Directors be paid out in cash and/or in the form of RSUs. The allocation option(s) between cash and RSU’s will be determined by the Board of Directors and set out in the individual short-term incentive agreement, provided that a minimum of one third (1/3) of the earned short-term incentive will be granted in the form of RSUs. RSUs will vest two years after grant as further specified by the Board of Directors.

The target value of the total short-term incentive granted as cash payment or in the form of RSUs, when meeting target performance, may not exceed 85% of the annual base salary including pension for the chief executive officer, and 70% of the annual base salary including pension for the other members of the Executive Board, in the year of the award.

The maximum value of the total short-term incentive granted as cash payment or in the form of RSUs may not exceed 120% of the annual base salary including pension for the chief executive officer, and 95% of the annual base salary including pension for the other members of the Executive Board, in the year of the award.

The value of the RSUs is calculated as described in the Company’s Remuneration Report. Chr. Hansen intends to buy back shares in order to cover its obligations in relation to the awarded RSUs.

4.2.2 Long-term incentive in the form of matching shares

To support the Company’s long-term objectives, members of the Executive Board may as a part of their remuneration be invited to participate in a matching shares program. The program will require the executive officer to purchase existing shares in Chr. Hansen (the “investment shares”) and retain ownership of the shares for a predefined holding period ending no later than at the expiration of the last financial year in the relevant reference period (which will cover at least three financial years).

Upon expiration of the holding period and subject to fulfillment of certain predefined performance targets, the executive officer will be entitled to receive a predefined number of additional shares per investment share (the “matching shares”). The matching shares program includes not only members of the Executive Board but also members of the Chr. Hansen Corporate Leadership Team.

The number of matching shares that may be received will be determined in advance based on specific performance targets defined by the Board of Directors in accordance with clause 2.3 above. The performance targets shall primarily relate to and support the Group’s long-term objectives. As a main rule the targets shall cover a minimum period of three financial years, provided that with regard to newly recruited members of the Executive Board, the year of employment may count as the first financial year notwithstanding that the person has only been employed for part of the year, subject to a minimum of six months.

Apart from satisfaction of the performance targets, receipt of any matching shares is conditional upon the executive officer:

- Having acquired a minimum of investment shares corresponding to a certain percentage of the annual base salary including pension of the executive officer, in the year of award.
- Having retained ownership of the investment shares throughout the holding period.
- Being employed with the Group upon expiration of the holding period or having left the Company prior thereto as a good leaver (as defined by the Board of Directors).
The expected value of the right to potentially receive matching shares may not at the time of award exceed 80% of the chief executive officer’s annual base salary including pension, and 60% of the annual base salary including pension for the other members of the Executive Board, in the year of award. The expected value is calculated as fair value based on achieving the target on all financial KPIs and a mid-range TSR performance (where applicable). Fair value is calculated as applied by Chr. Hansen in its Remuneration Report. The maximum value at time of grant may not exceed 125% of the chief executive officer’s annual base salary including pension, and 90% of the annual base salary including pension for the other members of the Executive Board, in the year of award.

The investment shares to be held by the executive officer may either be acquired on Nasdaq Copenhagen or other trading venues at market price in an open trading window, or constitute shares already owned by the relevant executive officer.

Chr. Hansen intends to buy back shares in order to cover its obligations in relation to the awarded matching shares.

4.3 Adjustments
For all incentive-based remuneration, the Board of Directors may decide that specific terms shall apply for accelerated vesting or exercise as well as for adjustment of incentive-based remuneration in case of a take-over in whole or in part, significant divestiture of activities, demerger, merger or other business combination involving Chr. Hansen. Finally, the Board of Directors may lay down terms governing adjustment of the exercise price, performance targets, etc. in the event that Chr. Hansen’s capital structure is changed, or in the event of other material events that would otherwise influence adversely the value or effect of the incentive-based remuneration.

4.4 Claw-back
The terms and conditions of the various types of incentive-based remuneration shall include specific terms governing the lapse of the scheme or repayment of the incentive-based remuneration, including lapse in the event that the executive officer resigns, or repayment/clawback in the event of errors in the accounting figures or other basis for the award or vesting under the scheme.

4.5 Deviations from the policy - award of extraordinary incentive-based remuneration
In order to meet the overall objectives for Chr. Hansen’s incentive-based remuneration programs, the Board of Directors may in individual extraordinary cases and when considered to be in the Company’s interest decide to award a one-off bonus, retention bonus, severance payment or a sign-on bonus in connection with recruitment, in each case disregarding the principles relating to the Company’s regular incentive programs set out in clauses 4.2.1 and 4.2.2. Such extraordinary awards may consist of cash and/or share-based remuneration and may or may not include performance criteria.

The value of extraordinary awards may not at the time of award exceed an amount corresponding to 85% of the executive officer’s annual base salary including pension in the year of award, provided that the award may be increased by an additional 85% of the executive officer’s annual base salary including pension in the year of award to the extent such increase relates to a sign-on bonus or other schemes in connection with recruitment.

4.6 Information on remuneration
Information on remuneration paid to the Executive Board, including information on base salary, pension, incentive-based remuneration as well as the Remuneration Policy, will be disclosed in Chr. Hansen’s Remuneration Report.
5. Adoption, publication, review and amendment of the Remuneration Policy

The Remuneration Policy has been adopted by the Board of Directors and approved by the shareholders of Chr. Hansen Holding A/S at the Annual General Meeting held on November 24, 2021. The only substantive amendment compared to the Remuneration Policy for Chr. Hansen Holding A/S adopted at the Annual General Meeting held November 27, 2019, is the inclusion of a new Section 2.6 (Directors’ and Officers’ Liability Insurance and Indemnification).

The Remuneration Policy is applicable to remuneration incentive programs with respect to the financial year 2021/22 and subsequent financial years.

The Remuneration Policy is available on the Company’s website www.chr-hansen.com, where the date of adoption also appears.

The Remuneration Policy will be reviewed on an annual basis by the Board of Directors’ Remuneration Committee. All changes to the Company’s Remuneration Policy must be adopted by the Board of Directors. Material changes must be approved by the Company’s shareholders at a General Meeting.

The Remuneration Policy must be approved by the General Meeting at least once every 4 years.
**Annex 2**

**Description of the candidates for the Board of Directors**

<table>
<thead>
<tr>
<th>Nationality</th>
<th>Gender</th>
<th>Born</th>
<th>Independence</th>
</tr>
</thead>
<tbody>
<tr>
<td>French</td>
<td>Female</td>
<td>July 1955</td>
<td>Yes</td>
</tr>
<tr>
<td>Danish</td>
<td>Male</td>
<td>October 1963</td>
<td>Yes</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Profession</th>
<th>Board competencies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Professional board member</td>
<td>Professional experience from positions in the food, beverage and hygiene/beauty care industries at, among others, Procter &amp; Gamble and Jacobs-Suchard (now Mondelēz International). 22 years in senior leadership positions at French and European levels within Coca-Cola Enterprises and The Coca-Cola Company. Experience from group management in a multinational pharmaceutical company, including responsibility for strategy development and implementation, legal affairs and patents, information technology and investor relations. Board and executive experience with financial reporting and capital markets.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Board positions and other offices</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair: Eurostar EIL, UK, chair of the nomination &amp; remuneration committee and member of the audit committee. Member: PayPal Luxembourg, LX, chair of the remuneration committee and member of the audit committee. Mondi plc, UK, chair of the sustainability committee and member of the nomination and remuneration committees. Deliveroo plc, UK, member of the audit and risk, nomination and remuneration committees.</td>
<td>Chair: Leo Pharma A/S, DK. Vice Chair: William Demant Invest A/S, DK Member: William Demant Fonden and the Advisory Board of the private equity company, VækstPartner Kapital ApS and the Danish Committee on Corporate Governance, all DK. Director of JBR Counselling ApS, DK.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Education</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>MBA from ESSEC Business School, Paris, F.</td>
<td>MSc. in Economics and Auditing, as well as an MBA, both from the Copenhagen Business School, DK.</td>
</tr>
</tbody>
</table>

*As defined in the Danish Recommendations on Corporate Governance.*
## Description of the candidates for the Board of Directors

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Nominated for re-election as a member of the Board of Directors</th>
<th>Member of the Board of Directors since</th>
<th>Chair of the Science &amp; Innovation Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luis Cantarell</td>
<td>Member</td>
<td></td>
<td>2016</td>
<td></td>
</tr>
<tr>
<td>Lise Kaae</td>
<td>Member</td>
<td></td>
<td>2020</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Nationality</th>
<th>Gender</th>
<th>Born</th>
<th>Independence*</th>
<th>Profession</th>
<th>Board competencies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spanish/Swiss</td>
<td>Male</td>
<td>August 1952</td>
<td>Yes</td>
<td>Professional board member</td>
<td>Professional global experience within the food and beverage industry, as well as the consumer health industry. Extensive board experience and over 10 years’ of executive leadership experience with the Nestlé Group.</td>
</tr>
<tr>
<td>Danish</td>
<td>Female</td>
<td>July 1969</td>
<td>Yes</td>
<td>CEO of Heartland A/S, DK</td>
<td>Extensive experience as a finance &amp; accounting professional. Ms. Kaae has been working as a state authorized public accountant and Partner for PwC, obtained operational CEO and CFO experience from the Bestseller Group, the Danish fashion wear company, and audit committee experience from Handelsbanken. Ms. Kaae further brings M&amp;A and investment experience.</td>
</tr>
</tbody>
</table>

|----------------------------------|------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|

| Education                      | Economic Sciences graduate from Universitat de Barcelona, Spain, and a graduate of the Program for Executive Development from IMD, CH. | MSc., Business Economics and Auditing, Aarhus School of Business and State Authorized Public Accountant, both DK. |

* As defined in the Danish Recommendations on Corporate Governance.
Description of the candidates for the Board of Directors

Heidi Kleinbach-Sauter – Member

Nominated for re-election as a member of the Board of Directors
Member of the Board of Directors since 2017
Member of the Science & Innovation Committee and the Nomination Committee

Nationality: German/US
Gender: Female
Born: June 1956
Independence*: Yes

Profession: Professional board member
Board competencies: More than 25 years of innovation and R&D experience across a broad range of categories within the CPG (consumer packaged goods) food and beverage industry in Europe, the US, Latin America, Asia and Australia. Founding Chair of several councils, including from listed companies. Experience as a member of the Advisory Committee of Northern Seed Montana LCC, US.

Board positions and other offices:
Member: Royal Unibrew A/S, DK.

Education:
Dr. Kleinbach-Sauter holds a degree as European Quality Manager and Auditor from the German Society of Quality Management. Further, she holds a BS, an MS and a PhD degree in Food Science and Food Technology from the University of Stuttgart-Hohenheim, D, and is a graduate of the General Management Program from Harvard Business School, US.

Kevin Lane – Member

Nominated for re-election as a member of the Board of Directors
Member of the Board of Directors since 2020
Member of the Nomination and the Science & Innovation Committee

Nationality: Irish
Gender: Male
Born: February 1965
Independence*: Yes

Profession: Professional board member
Board competencies: Extensive CEO experience within the food sector. This especially covers dairy, from Ornua Co-operative Ltd. the Irish dairy co-operative, and the food ingredients sector from the Kerry Group, the Irish food ingredients and flavor manufacturer. Mr. Lane brings international experience from being based in London, Mexico, Central America and the US during his time in the Kerry Group. He further has extensive M&A experience and a good mix of both B2B and B2C experience.

Board positions and other offices:
Chair: Fiid (eatfiid.com), IRL
Member: Wheatsheaf Investments Ltd. and chair of the investment committee, IRL.
Senior advisor for PAI Partners, F, and member of the IE Brown Executive MBA Advisory Committee, IRL.

Education:
MSc., Business, Sales and Marketing, University of Limerick, IRL.

* As defined in the Danish Recommendations on Corporate Governance.
Description of the candidates for the Board of Directors

Lillie Li Valeur – Member

Nominated for re-election as a member of the Board of Directors
Member of the Board of Directors since 2020
Member of the Remuneration and Science & Innovation Committee

<table>
<thead>
<tr>
<th>Nationality</th>
<th>Danish Chinese</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>Female</td>
</tr>
<tr>
<td>Born</td>
<td>February 1970</td>
</tr>
<tr>
<td>Independence*</td>
<td>No (affiliated with Novo Holdings A/S)</td>
</tr>
<tr>
<td>Profession</td>
<td>CEO of Good Food Group A/S</td>
</tr>
<tr>
<td>Board competencies</td>
<td>CEO experience at the helm of Good Food Group A/S and non-executive director experience from AAK AB, the Swedish plant-based oils and fats company, and MEDA AB, the Swedish pharmaceutical company. She further has a strong dairy and pharmaceutical background from a range of managerial positions at Arla Foods and Novartis. In addition, Ms. Valeur brings international experience with focus on Asia and EMEA, as well as a good balance of B2C and B2B experience.</td>
</tr>
<tr>
<td>Board positions and other offices</td>
<td>Member: Marel Hf (chair of nomination committee and member of remuneration committee), IS, the Danish Food and Drink Federation and the Association of Danish General Industries.</td>
</tr>
<tr>
<td>Education</td>
<td>MBA from CEIBS and BA in Medicine, Shanghai Medical University, both CHN.</td>
</tr>
</tbody>
</table>

*As defined in the Danish Recommendations on Corporate Governance.
Description of the elected group representatives until 2025

<table>
<thead>
<tr>
<th></th>
<th>Casper Lynghej Giedo</th>
<th>Charlotte Hemmingsen</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Member of the Board of Directors</strong></td>
<td>following the AGM in November 2021</td>
<td>since 2017</td>
</tr>
<tr>
<td><strong>Nationality</strong></td>
<td>Danish</td>
<td>Danish</td>
</tr>
<tr>
<td><strong>Gender</strong></td>
<td>Male</td>
<td>Female</td>
</tr>
<tr>
<td><strong>Born</strong></td>
<td>June 1982</td>
<td>September 1964</td>
</tr>
<tr>
<td><strong>Independence</strong></td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td><strong>Profession</strong></td>
<td>Principal Specialist, Global Operation, Chr. Hansen A/S</td>
<td>Senior Specialist, CMC Documentation, QA, Chr. Hansen A/S</td>
</tr>
<tr>
<td><strong>Board competencies</strong></td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Board positions and other offices</strong></td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Education</strong></td>
<td>Diploma in biotechnology, process technology and chemistry from University of Southern Denmark, DK.</td>
<td>Master of Science (Agro) from The Royal Danish Veterinarian and Agricultural University, DK.</td>
</tr>
</tbody>
</table>

* As defined in the Danish Recommendations on Corporate Governance.
** Employee representative elected by the employees of Chr. Hansen Holding A/S and Chr. Hansen A/S.
Description of the elected group representatives until 2025

Karen Louise Lauesen  
- Employee representative**

Member of the Board of Directors following the AGM in November 2021

<table>
<thead>
<tr>
<th>Nationality</th>
<th>Gender</th>
<th>Born</th>
<th>Independence*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Danish</td>
<td>Female</td>
<td>December 1977</td>
<td>No</td>
</tr>
</tbody>
</table>

Profession: Head of Organizational Communications, Chr. Hansen A/S

<table>
<thead>
<tr>
<th>Board competencies</th>
<th>-</th>
<th>-</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Board positions and other offices</th>
<th>-</th>
<th>-</th>
</tr>
</thead>
</table>

Education: B.A. Hons in French and Spanish from Royal Holloway University of London, UK and certified change management practitioner.

Kim Ib Sørensen  
- Employee representative**

Member of the Board of Directors since 2017

<table>
<thead>
<tr>
<th>Nationality</th>
<th>Gender</th>
<th>Born</th>
<th>Independence*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Danish</td>
<td>Male</td>
<td>July 1963</td>
<td>No</td>
</tr>
</tbody>
</table>

Profession: Senior Principal Scientist with responsibilities within bacterial strain development and acquisition, Chr. Hansen A/S

<table>
<thead>
<tr>
<th>Board competencies</th>
<th>-</th>
<th>-</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Board positions and other offices</th>
<th>-</th>
<th>-</th>
</tr>
</thead>
</table>

Education: Master of Science in Biochemistry and a Ph.D. in Molecular Biology from the University of Copenhagen, DK.

---

* As defined in the Danish Recommendations on Corporate Governance.
** Employee representative elected by the employees of Chr. Hansen Holding A/S and Chr. Hansen A/S.
Delivering value for more than 145 years

Chr. Hansen has been fermenting lactic acid bacteria for more than a century, and working with clinically documented probiotics for more than 25 years.

We serve customers worldwide with expertise, new ideas, professional support and customized solutions – all aimed at ensuring superior product portfolios and business success in probiotics.

Chr. Hansen Holding A/S
Bøge Allé 10-12, 2970 Hørsholm, Denmark
Phone: +45 4574 7474

Find and follow

www.youtube.com/user/dkchrhansen
www.linkedin.com/company/chr-hansen-as
www.twitter.com/chr_hansen
www.facebook.com/chr.hansen.group
www.instagram.com/chr.hansen
www.chr-hansen.com